Cornerstone Therapeutics

This page shows the latest Cornerstone Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Chiesi hits the acquisition trail again

company Cornerstone Therapeutics. ... The value of the deal is around $107m and all in all values Cornerstone at some $255m.

Biologics buoyant

Three of the deals, with Amplimmune, FivePrime Therapeutics and Genmab, focus on biologics. ... 84+. Cornerstone Therapeutics/Targacept . Alpha-7 and other nicotinic receptor targeting compounds. Preclinical .

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Deal Watch table for September 2013

Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... Cornerstone Therapeutics, respectively.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

No results were found

Add my company

We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story: ...
New Playbook Alert: Virtual Patient Engagement: ...
Millennials: the wellness generation: Looking at the results from a global healthcare research study focusing on the patients of the future...

Email:
Password: